@selenaalexisss's tirzepatide predictions, fact-checked
Quick answer
The video's caption indicates the creator is using a GLP-1 or dual GIP/GLP-1 medication, likely tirzepatide, through a telehealth platform called Freya, and is experiencing ongoing weight loss. No specific clinical claims about dosing, mechanism, or outcomes were made in the spoken audio. The content functions as a personal progress post rather than medical information.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @selenaalexisss actually say?
Straight answer: the transcript contains no medical claims about GLP-1 medications, tirzepatide, or weight loss. The video caption references GLP-1 use and excitement about upcoming weight loss, but the spoken audio is song lyrics, not health information.
The creator's caption reads "Did my happy dance at the end because I know ima lose some more pounds this week" and tags a platform called Freya, using hashtags like #glp1forweightloss and #tirzepatide. That context tells us this is a GLP-1 journey video. But the transcript itself, word for word, is a music track. There are no spoken claims about dosing, efficacy, side effects, or medication comparisons to evaluate.
This is worth being precise about. Fact-checking a song played over a weight loss video is not the same as fact-checking health advice. The caption's emotional framing, "I know ima lose some more pounds this week," is personal enthusiasm, not a medical claim.
Does the science back this up?
There is solid evidence that GLP-1 receptor agonists like tirzepatide produce meaningful weight loss, but the creator didn't actually make a scientific claim here, so this is context, not a correction.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has shown strong clinical results. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found participants on the highest dose (15 mg weekly) lost a mean of 20.9% of body weight over 72 weeks. That is genuinely significant data. The SURMOUNT-2 trial extended similar findings to people with type 2 diabetes.
The general sentiment that tirzepatide works for weight loss in the right clinical context? That's supported. But the creator didn't cite a mechanism, make a dosing claim, or compare tirzepatide to other drugs. They danced to a song. The science is relevant background, not a verdict on what was said.
What did they get wrong (or right)?
Nothing was technically wrong because nothing was technically claimed. But the broader content pattern here deserves scrutiny even if this specific video dodges it.
GLP-1 content on TikTok, broadly, has a documented accuracy problem. A 2023 analysis of social media GLP-1 content found that a significant proportion of popular posts contained misleading dosing information or unsupported claims about weight loss timelines. This video doesn't do that. The caption is emotional and personal, which is legitimate. Sharing a journey is different from giving medical advice.
One thing worth flagging: the Freya tag suggests this is branded or affiliate content for a telehealth platform. If creators are compensated to post GLP-1 journey content, the FTC requires disclosure. There is no visible #ad or #sponsored tag in the provided hashtags. That is a compliance gap worth noting, even if it is not a medical accuracy issue.
What should you actually know?
If you are considering GLP-1 therapy because of videos like this one, here is what the evidence actually says, without the happy dance.
Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It requires a prescription and medical supervision. Compounded versions of tirzepatide exist, but they are not FDA-approved and are not equivalent to brand-name Zepbound. Do not treat them as interchangeable.
- Weight loss results vary significantly. The SURMOUNT-1 trial showed a range, not a guaranteed outcome.
- Side effects, primarily nausea, vomiting, and gastrointestinal issues, affect a meaningful portion of users and can lead to discontinuation.
- Weight often returns after stopping the medication (Wilding et al., 2022, Diabetes, Obesity and Metabolism).
- These medications work best alongside dietary changes and are not a standalone fix.
Watching someone's weight loss journey on TikTok can be motivating. It is not a substitute for a clinical evaluation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @selenaalexisss's tirzepatide predictions, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The video's caption indicates the creator is using a GLP-1 or dual GIP/GLP-1 medication, likely tirzepatide, through a telehealth platform called Freya, and is experiencing ongoing weight loss.
FormBlends verdict
The video's caption indicates the creator is using a GLP-1 or dual GIP/GLP-1 medication, likely tirzepatide, through a telehealth platform called Freya, and is experiencing ongoing weight loss. No specific clinical claims about dosing, mechanism, or outcomes were made in the spoken audio. The content functions as a personal progress post rather than medical information.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video's caption indicates the creator is using a GLP-1 or dual GIP/GLP-1 medication, likely tirzepatide, through a telehealth platform called Freya, and is experiencing ongoing weight loss. No specific clinical claims about dosing, mechanism, or outcomes were made in the spoken audio. The content functions as a personal progress post rather than medical information.
- This video contains no spoken medical claims. The transcript is song lyrics, making traditional fact-checking of health claims inapplicable.
- Tirzepatide produced an average 20.9% body weight reduction at the highest dose in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), supporting the general premise of GLP-1 weight loss journeys.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- This video contains no spoken medical claims. The transcript is song lyrics, making traditional fact-checking of health claims inapplicable.
- Tirzepatide produced an average 20.9% body weight reduction at the highest dose in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), supporting the general premise of GLP-1 weight loss journeys.
- The video appears to be affiliated with telehealth platform Freya but carries no visible FTC-required disclosure hashtags like #ad or #sponsored.
- Compounded tirzepatide is not FDA-approved and is not equivalent to brand-name Zepbound. Patients should not assume parity between the two.
- Weight regain after discontinuing GLP-1 therapy is well-documented. Wilding et al. (2022, Diabetes, Obesity and Metabolism) found significant weight return after stopping semaglutide.
- Social media GLP-1 content drives patient interest but frequently lacks context about side effects, eligibility criteria, and the need for ongoing medical supervision.
- Individual weekly weight loss on tirzepatide is not predictable from clinical trial averages. Personal timelines shown on TikTok should not be treated as expected outcomes.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Selena Jackson · TikTok creator
44.7K views on this video
Did my happy dance at the end because I know ima lose some more pounds this week 🥹 @Freya 👈 • • • #glp1 #glp1forweightloss #glp1community #tirzepatide #freya #weightloss #weightlossjouney #fitnes
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Selena Jackson, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.